Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04511130 · ClinicalTrials.gov registry record · Phase 2
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
A Phase 2 study, sponsored by Marker Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT04511130 is a Phase 2 study that was terminated before completion, run by Marker Therapeutics. The registered enrollment target is 92 participants.
The verdict
NCT04511130, a Phase 2 study, was terminated before completion, sponsored by Marker Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10\^6 cells (flat dosing).
Interventions
- DRUG MT-401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04511130
The ClinicalTrials.gov registry entry for NCT04511130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marker Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-401 is the first listed.
NCT04511130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04511130 about?
NCT04511130 is a clinical study titled "Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant". This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10\^6 cells (flat dosing).
What is the current status of trial NCT04511130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2020-10-14. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04511130?
The interventions under investigation include: MT-401 (DRUG).
Who is sponsoring clinical trial NCT04511130?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.